hrs4r
Quiero donar

JOSEP MARIA RONCERO VIDAL

Firma
JOSEP MARIA RONCERO-VIDAL
Posición
Investigadors/es Col·laboradors/es
Investigadores/as Colaboradores/as

Publicacions

0

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117, 388-397 dx.doi.org/10.1007/s12185-022-03488-5

Villavicencio A, Solans M, Zacarías-Pons L, Vidal A, Puigdemont M, Roncero JM, Saez M, Marcos-Gragera R

Comorbidities at Diagnosis, Survival, and Cause of Death in Patients with Chronic Lymphocytic Leukemia: A Population-Based Study

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 dx.doi.org/10.3390/ijerph18020701

Negre Busó M, Balliu Collgrós E, Ferran Sureda N, Velasco Nuño M, Roncero Vidal JM, Rubió Rodríguez A

Follicular dendritic cell tumor in the context of a Castleman disease in a patient with Diffuse Large B Cell Lymphoma: Diagnosis and follow-up with 18 F-FDG PET/CT.

Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 322-324 dx.doi.org/10.1016/j.remnie.2020.08.003

Negre Busó M, Balliu Collgrós E, Rubió Rodríguez A, Peláez Hernández I, Mestre Fusco A, Roncero Vidal JM

Utility of the 18 F-FDG PET/CT in the diagnosis of the neurolymphomatosis: A case report.

Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 328-331 dx.doi.org/10.1016/j.remnie.2020.09.017

Negre Busó M, Balliu Collgrós E, Rubió Rodríguez A, Peláez Hernández I, Mestre Fusco A, Roncero Vidal JM

Utility of the F-18-FDG PET/CT in the diagnosis of the neurolymphomatosis: a case report

REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2020, 40, 328-331 dx.doi.org/10.1016/j.remn.2020.06.021

Villavicencio A, Solans M, Auñon-Sanz C, Roncero JM, Marcos-Gragera R

Population-based survival of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain

CANCER EPIDEMIOLOGY, 2020, 69, 101841-101841 dx.doi.org/10.1016/j.canep.2020.101841

O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR, Lumiere Study Investigators

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37, 613-623 dx.doi.org/10.1200/JCO.18.00899

Solans M, Fàbrega A, Morea D, Auñon-Sanz C, Granada I, Roncero JM, Blanco A, Kelleher N, Buch J, Saez M, Marcos-Gragera R

Population-based incidence of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain

CANCER EPIDEMIOLOGY, 2019, 58, 8-11 dx.doi.org/10.1016/j.canep.2018.11.001

Solans M, Osca-Gelis G, Comas R, Roncero JM, Gallardo D, Marcos-Gragera R, Saez M

Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the province of Girona, Spain

CANCER CAUSES & CONTROL, 2018, 29, 379-382 dx.doi.org/10.1007/s10552-018-1004-5

Formulari de contacte

Conoce el IDIBGI!

menu